Votrient pazopanib: Phase III data

The double-blind, international Phase III PALETTE trial in 369 patients with angiogenesis inhibitor-naïve, metastatic STS who progressed following chemotherapy showed that once-daily 800 mg Votrient met the primary endpoint of median PFS vs. placebo (4.6 vs. 1.6 months, p<0.0001). Votrient missed the secondary endpoint of median OS vs. placebo (12.5 vs. 10.7 months, p=0.25). The most common adverse events were fatigue, diarrhea, nausea, weight loss and hypertension. Additionally, of 8 fatal adverse events in patients receiving Votrient, 1 was a case of multi-organ failure that might have been related to treatment. Data were published in The Lancet. ...